• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Viruses, Vol. 15, Pages 105: Topoisomerase II as a Novel Antiviral Target against Panarenaviral Diseases
ro Yasuda Although many arenaviruses cause severe diseases with high fatality rates each year, treatment options are limited to off-label use of ribavirin, and a Food and Drug Administration (FDA)-approved vaccine is not available. To identify novel therapeutic candidates against arenaviral diseases, an RNA polymerase I-driven minigenome (MG) expression system for Lassa virus (LASV) was developed and optimized for high-throughput screening (HTS). Using this system, we screened 2595 FDA-approved compounds for inhibitors of LASV genome replication and identified multiple compounds including pixantrone maleate, a topoisom...
Source: Viruses - December 30, 2022 Category: Virology Authors: Tosin Oladipo Afowowe Yasuteru Sakurai Shuzo Urata Vahid Rajabali Zadeh Jiro Yasuda Tags: Article Source Type: research

Lifecycle modelling systems support inosine monophosphate dehydrogenase (IMPDH) as a pro-viral factor and antiviral target for New World arenaviruses
Publication date: Available online 19 July 2018Source: Antiviral ResearchAuthor(s): Eric C. Dunham, Anne Leske, Kyle Shifflett, Ari Watt, Heinz Feldmann, Thomas Hoenen, Allison GrosethAbstractInfection with Junín virus (JUNV) is currently being effectively managed in the endemic region using a combination of targeted vaccination and plasma therapy. However, the long-term sustainability of plasma therapy is unclear and similar resources are not available for other New World arenaviruses. As a result, there has been renewed interest regarding the potential of drug-based therapies. To facilitate work on this issue, we presen...
Source: Antiviral Therapy - July 20, 2018 Category: Virology Source Type: research

Lifecycle modelling systems support inosine monophosphate dehydrogenase (IMPDH) as a pro-viral factor and antiviral target for New World arenaviruses.
Abstract Infection with Junín virus (JUNV) is currently being effectively managed in the endemic region using a combination of targeted vaccination and plasma therapy. However, the long-term sustainability of plasma therapy is unclear and similar resources are not available for other New World arenaviruses. As a result, there has been renewed interest regarding the potential of drug-based therapies. To facilitate work on this issue, we present the establishment and subsequent optimization of a JUNV minigenome system to a degree suitable for high-throughput miniaturization, thereby providing a screening platform f...
Source: Antiviral Research - July 19, 2018 Category: Virology Authors: Dunham EC, Leske A, Shifflett K, Watt A, Feldmann H, Hoenen T, Groseth A Tags: Antiviral Res Source Type: research